Skip to main content
SpringerLink
Log in

Pharmacokinetics of Anticancer Drugs in Children

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Interpatient pharmacokinetic variability normally observed in adults is often of even greater magnitude in paediatric patients because of age-related maturation of physiological processes responsible for drug disposition. Several antineoplastic agents have shown age-related changes, including alterations in volume of distribution, hepatic (doxorubicin, cyclophosphamide), and renal (bleomycin, methotrexate) clearances. These differences in pharmacokinetics as a function of age alter systemic exposure to chemotherapy, and may alter the efficacy and toxicity profile for standard doses of antineoplastic drugs.

The relationship of systemic exposure to toxicity has been most clearly defined for methotrexate. Clinical monitoring of methotrexate serum concentrations, and adjustment of folinic acid dosages and duration of rescue based on methotrexate disposition is now routine. More recently, pharmacodynamic data have been published for high-dose methotrexate, epipodophyllotoxins, cisplatin, and cytarabine (cytosine arabinoside), indicating a relation between drug disposition and toxicity or efficacy. Collectively, these data suggest that the pharmacokinetics of many anticancer drugs in children is different from adults, and that variability in drug disposition may have an important influence on toxicity or efficacy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Abdella BRJ, Fisher J. A chemical perspective on the anthracyclin antitumour antibiotics. Environmental Health Perspective 64: 3–18, 1985

    Article  CAS  Google Scholar 

  • Adams JD, Hunter GA. Drug interactions in psoriasis. Australian Journal of Dermatology 17: 39–40, 1976

    Article  CAS  Google Scholar 

  • Alberts DS, Bachur NR, Holtzman JL. The pharmacokinetics of daunomycin in man. Clinical Pharmacology and Therapeutics 12: 96–104, 1972

    Google Scholar 

  • Alberts DS, Chen HSG, Liv R, et al. Bleomycin pharmacokinetics in man. Cancer Chemotherapy and Pharmacology 1: 1–5, 1978

    Article  Google Scholar 

  • Allen LM, Creaven PJ. Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivatives. European Journal of Cancer 11: 697–707, 1975

    Article  PubMed  CAS  Google Scholar 

  • Allen LM, Tejada F, Okonmah AD, Nordqvist S. Combination chemotherapy of the epipodophyllotoxin derivatives, teniposide and etoposide: a pharmacodynamic rationale? Cancer Chemotherapy and Pharmacology 7: 151–156, 1982

    Article  PubMed  CAS  Google Scholar 

  • Anderson LL, Collins GJ, Ojima Y, Sullivan RD. A study of the distribution of methotrexate in human tissues and tumors. Cancer Research 30: 1344–1348, 1970

    PubMed  CAS  Google Scholar 

  • Arbuck SG, Douglass HO, Crom WR, Goodwin P, Silk Y, et al. Etoposide pharmacokinetics in patients with normal and abnormal liver function. Journal of Clinical Oncology, in press, 1986

    Google Scholar 

  • Arcamone F. Properties of antitumor anthracyclines and new developments in their application: Cain Memorial Award Lecture. Cancer Research 45: 5995–5999, 1985

    PubMed  CAS  Google Scholar 

  • Arnold AM. Podophyllotoxin derivative VP 16-213. Cancer Chemotherapy and Pharmacology 3: 71–80, 1979

    Article  PubMed  CAS  Google Scholar 

  • Bachur NR. Adriamycin (NSC-123127) pharmacology. Cancer Chemotherapy Reports 6(2): 153–158, 1975

    CAS  Google Scholar 

  • Bachur NR. Anthracycline antibiotic pharmacology and metabolism. Cancer Treatment Reports 63(5): 817–820, 1979

    PubMed  CAS  Google Scholar 

  • Bachur NR, Riggs CE, Green MR, et al. Plasma adriamycin and daunorubicin levels by fluorescence and radioimmunoassay. Clinical Pharmacology and Therapeutics 21: 70–77, 1977

    PubMed  CAS  Google Scholar 

  • Bagley CM, Bostick FW, De Vita VT. Clinical pharmacology of cyclophosphamide. Cancer Research 33: 226–233, 1973

    PubMed  Google Scholar 

  • Balis FM, Savitch JL, Bleyer WA. Pharmacokinetics of oral methotrexate in children. Cancer Research 43: 2342–2345, 1983

    PubMed  CAS  Google Scholar 

  • Baxter JD, Forsham PH. Tissue effects of glucocorticoids. American Journal of Medicine 53: 573–589, 1972

    Article  PubMed  CAS  Google Scholar 

  • Beach BJ, Wood WG, Howell SB. Influence of co-trimoxazole on methotrexate pharmacokinetics in children with acute lymphoblastic leukemia. American Journal of Pediatric Hematology/Oncology 2: 115–119, 1981

    Article  Google Scholar 

  • Belt RJ, Himmelstein KJ, Patton TF, Bannister SJ, Sternson LA, et al. Pharmacokinetics of non-protein-bound platinum species following administration of cis-dichlorodiammineplatinum (II). Cancer Treatment Reports 63: 1515–1521, 1979

    PubMed  CAS  Google Scholar 

  • Bender RA, Castle MC, Margleth DA, Oliverio VT. The pharmacokinetics of [3H]-vincristine in man. Clinical Pharmacology and Therapeutics 22: 430–438, 1977

    PubMed  CAS  Google Scholar 

  • Bending MR, Finch RE. Haemodialysis during cyclophosphamide treatment. British Medical Journal 1: 1145–1146, 1978

    Article  PubMed  CAS  Google Scholar 

  • Benjamin RS. Pharmacokinetics of adriamycin (SCN 123127) in patients with sarcomas. Cancer Chemotherapy Reports 58: 271–273, 1974

    CAS  Google Scholar 

  • Benjamin RS. A practical approach to adriamycin (NSC 123127) toxicology. Cancer Chemotherapy Reports 6: 191–194, 1975a

    Google Scholar 

  • Benjamin RS. Clinical pharmacology of adriamycin (NSC 123127). Cancer Chemotherapy Reports 6: 183–185, 1975b

    Google Scholar 

  • Benjamin RS, Riggs Jr CE, Bachur NR. The pharmacokinetics and metabolism of adriamycin in man. Clinical Pharmacology and Therapeutics 14: 592–600, 1973

    PubMed  CAS  Google Scholar 

  • Benjamin RS, Riggs Jr CE, Bachur NR. Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. Cancer Research 37: 1416–1420, 1977

    PubMed  CAS  Google Scholar 

  • Benjamin RS, Wiernik PH, Bachur NR. Adriamycin chemotherapy-efficacy, safety, and pharmacologic basis of an intermittent single high-dose schedule. Cancer 33: 19–27, 1974

    Article  PubMed  CAS  Google Scholar 

  • Bertino JR. Techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. Seminars on Oncology 4: 203–216, 1977

    CAS  Google Scholar 

  • Bertino JR. Methotrexate: clinical pharmacology and therapeutic application. In Crooke & Prestayko (Eds) Cancer and chemotherapy, Vol. III, pp. 359–375, Academic Press, New York, 1981

    Google Scholar 

  • Bischoff KB, Dedrick RL, Zuharko DS, et al. Methotrexate pharmacokinetics. Journal of Pharmaceutical Sciences 60: 1128–1133, 1971

    Article  PubMed  CAS  Google Scholar 

  • Blum RH, Carter SK. Adriamycin: a new anticancer drug with significant clinical activity. Annals of Internal Medicine 80: 249–259, 1974

    PubMed  CAS  Google Scholar 

  • Blum RH, Carter SK, Agre K. A clinical review of bleomycin — a new antineoplastic agent. Cancer 31: 903–914, 1973

    Article  PubMed  CAS  Google Scholar 

  • Bonadonna G, Delena M, Monfardini S, Bartoli C, Bajetta E, et al. Clinical trials with bleomycin in lymphomae and in solid tumors. European Journal of Cancer 8: 205–215, 1972

    Article  PubMed  CAS  Google Scholar 

  • Bonadonna G, Monfardini S, DeLana M, Fossati-Bellani F, Beretta G. Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Research 30: 2572–2582, 1970

    PubMed  CAS  Google Scholar 

  • Bonadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. New England Journal of Medicine 304: 10–15, 1981

    Article  PubMed  CAS  Google Scholar 

  • Bourke RS, Cheda G, Bremer A, et al. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Research 35: 110–116, 1975

    PubMed  CAS  Google Scholar 

  • Bramwell V, Calvert RT, Edwards G, et al. The disposition of cyclophosphamide in a group of myeloma patients. Cancer Chemotherapy and Pharmacology 3: 253–259, 1979

    Article  PubMed  CAS  Google Scholar 

  • Breithaupt H, Kuenzlen E. Pharmacokinetics of methotrexate and 7-hydroxy-methotrexate following infusions of high-dose methotrexate. Cancer Treatment Reports 66: 1733–1941, 1982

    PubMed  CAS  Google Scholar 

  • Brenner DE, Grosh WW, Noone R, Stein R, Greco A, et al. Human plasma pharmacokinetics of doxorubicin: comparison of bolus and infusional administration. Cancer Treatment Symposia 3: 77–83, 1984

    Google Scholar 

  • Brindley CJ, Antonin P, Newlands ES, Bagshawe KD. Pharmacokinetics and toxicity of the epipodophyllotoxin derivative etoposide (VP-16-213) in patients with gestational choriocarcinoma and malignant teratoma. Cancer Chemotherapy and Pharmacology 15: 66–71, 1985

    Article  PubMed  CAS  Google Scholar 

  • Brindley CO, Salvin LG, Potee KG, et al. Further comparative trial of triethylene thiophosphoramide and mechlorethamine in patients with melanoma and Hodgkin’s disease. Journal of Chronic Diseases 17: 19–30, 1964

    Article  PubMed  CAS  Google Scholar 

  • Brock N, Stekar J, Phol J, Neimeyer U, Scheffler G. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosphamide, trofosfamide and sufosfamide. Arzneimittel-Forschung 29: 659–661, 1979

    PubMed  CAS  Google Scholar 

  • Broggini M, Colombo T, D’Incalci M. Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice. Cancer Treatment Reports 67: 555–559, 1983

    PubMed  CAS  Google Scholar 

  • Broggini M, Rossi C, Benefenati E, D’Incalci M, Fanelli R, et al. Horseradish peroxidase/hydrogen peroxide-catalyzed oxidation of VP16-213: identification of a new metabolite. Chemico-Biological Interactions 55: 215–224, 1985

    Article  PubMed  CAS  Google Scholar 

  • Broughton A, Strong JE, Holoye PY, Bedrossian CWM. Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. Cancer 40: 2772–2778, 1977

    Article  PubMed  CAS  Google Scholar 

  • Brunner KW, Sonntag RW, Ryssel HJ, Cavalli F. Comparison of the biologic activity of VP-16-213 given IV and orally in capsules or drink ampules. Cancer Treatment Reports 60: 1377–1379, 1976

    PubMed  CAS  Google Scholar 

  • Buckner CK, Rudolph RH, Fefer A, et al. High dose cyclophosphamide therapy for malignant disease: toxicity, tumor response, and the effects of stored autologous marrow. Cancer 29: 357–365, 1972

    Article  Google Scholar 

  • Burger RM, Peisach J, Horwitz SB. Mechanisms of bleomycin action: in vitro studies. Life Sciences 28: 715–727, 1981

    Article  PubMed  CAS  Google Scholar 

  • Campbell AB, Kaiman SM, Jacobs C. Plasma platinum levels: relationship to cisplatin dose and nephrotoxicity. Cancer Treatment Reports 67: 169–172, 1983

    PubMed  CAS  Google Scholar 

  • Campbell MA, Perrier DG, Dorr RT, Alberts DS, Finley PR. Methotrexate: bioavailability and pharmacokinetics. Cancer Treatment Reports 69: 833–838, 1985

    PubMed  CAS  Google Scholar 

  • Campbell TN, Howell SB, Pfeifle CE, Hung WE, Bookstein J. Clinical pharmacokinetics of intraarterial cisplatin in humans. Journal of Clinical Oncology 1: 755–762, 1983

    PubMed  CAS  Google Scholar 

  • Canal P, Bugat C, Roche MH, Soula G, Combes PF. Pharmacokinetics of teniposide (VM-26) after IV administration in serum and malignant ascites of patients with ovarian carcinoma. Cancer Chemotherapy and Pharmacology 15: 149–152, 1985

    Article  PubMed  CAS  Google Scholar 

  • Canetta R, Hilgard P, Florentine S, Bedogni P, Lenaz L. Current development of podophyllotoxins. Cancer Chemotherapy and Pharmacology 7: 93–98, 1982

    Article  PubMed  CAS  Google Scholar 

  • Carde P, MacKintosh FR, Rosenberg SA. A dose and time response analysis of the treatment of Hodgkin’s disease with MOPP chemotherapy. Journal of Clinical Oncology 1: 146–153, 1983

    PubMed  CAS  Google Scholar 

  • Casazza AM. Preclinical selection of new anthracyclines. Cancer Treatment Reports 70: 43–49, 1986

    PubMed  CAS  Google Scholar 

  • Castle MC, Mead JAR. Investigations of the metabolic fate of titrated vincristine in the rat by high-pressure liquid chromatography. Biochemical Pharmacology 27: 37–44, 1978

    Article  PubMed  CAS  Google Scholar 

  • Chabner BA, Young RC. Threshold methotrexate concentrations for in vivo inhibition of DNA synthesis in normal and tumorous target tissues. Journal of Clinical Investigation 52: 1804–1811, 1973

    Article  PubMed  CAS  Google Scholar 

  • Chan KK, Cohen JL, Gross JF, Himmelstein KJ, Bateman JR, et al. Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model. Cancer Treatment Reports 62(8): 1161–1171, 1978

    PubMed  CAS  Google Scholar 

  • Chan KK, Nayer MS, Cohen JL, et al. Metabolism of methotrexate in man after high and conventional doses. Research Community of Chemistry, Pathology, and Pharmacology 28: 551–561, 1980

    CAS  Google Scholar 

  • Chauncey TR, Showel AL, Fox JH. Vincristine neurotoxicity. Correspondence. Journal of the American Medical Association 254: 507, 1985

    Article  CAS  Google Scholar 

  • Chauvet M, Bourdeaux M, Briand C, Dell’Amico M, Gilli R, et al. Interaction of MTX metabolites with beef liver dihydrofolate reductase-I. Biochemical Pharmacology 32: 1059–1062, 1983

    Article  PubMed  CAS  Google Scholar 

  • Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. Journal of Biological Chemistry 259(21): 13560–13566, 1984

    PubMed  CAS  Google Scholar 

  • Chen ML, McQuire WP, Lad TE, et al. A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients. International Journal of Clinical Pharmacology and Therapeutic Toxicology 22: 1–6, 1984

    CAS  Google Scholar 

  • Chou TH, Yost C. Adriamycin resistance in murine leukemia P388 cells and increased DNA repair. Proceedings of the American Association of Cancer Research 26: 217, 1985

    Google Scholar 

  • Christophidis N, Vaida FJE, Lucas I, et al. Comparison of intravenous and oral high-dose methotrexate in treatment of solid tumors. British Medical Journal 1: 298–300, 1979

    Article  PubMed  CAS  Google Scholar 

  • Coassolo P, Valentin M, Bourdeaux M, Briand C. Modification of human serum albumin binding of methotrexate by folinic acid and certain drugs used in cancer chemotherapy. European Journal of Clinical Pharmacology 17: 123–127, 1980

    Article  PubMed  CAS  Google Scholar 

  • Cohen JL, Jao JY, Jusko WJ. Pharmacokinetics of cyclophosphamide in man. British Journal of Pharmacology 43: 677–680, 1971

    Article  PubMed  CAS  Google Scholar 

  • Cohen MH, Creaven PF, Fossieck BE, et al. Effect of oral prophylactic broad spectrum nonabsorbable antibiotics on the gastrointestinal absorption of nutrients and methotrexate in small cell bronchogenic cancer. Cancer 38: 1556–1559, 1976

    Article  PubMed  CAS  Google Scholar 

  • Cohen MH, Creaven PF, Fossieck BE, et al. Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treatment Reports 61: 349–354, 1977

    PubMed  CAS  Google Scholar 

  • Collier CP, MacLeod SM, Soldin SJ. Analysis of methotrexate and 7-hydrox y methotrexate by high-performance liquid chromatography and preliminary clinical studies. Therapeutic Drug Monitoring 4: 371–380, 1982

    Article  PubMed  CAS  Google Scholar 

  • Colombo T, Broggini M, Vaghi M, Amato G, Erba E, et al. Comparison between VP 16 and VM 26 in Lewis lung carcinoma of the mouse. European Journal of Cancer and Clinical Oncology 22: 173–179, 1986

    Article  CAS  Google Scholar 

  • Colvin M, Brundrett RB, Kan MNN, Jardine I, Fenselan C. Alkylating properties of phosphoramide mustard. Cancer Research 36: 1121–1126, 1976

    PubMed  CAS  Google Scholar 

  • Colvin M, Padgett CA, Fenselan C. A biologically active metabolite of cyclophosphamide. Cancer Research 33: 915–918, 1973

    PubMed  CAS  Google Scholar 

  • Comis RL. Bleomycin pulmonary toxicity. In Carter et al. (Eds) Bleomycin: current status and new developments, p. 286, Academic Press, New York, 1978

    Google Scholar 

  • Comis RL. Cisplatin nephrotoxicity: the effect of dose, schedule, and hydration scheme. In Prestayko et al. (Eds) Cisplatin: current status and new developments, pp. 485–494, Academic Press Inc., New York, 1980

    Google Scholar 

  • Conner TA, Cox PJ, Farmer PB, Foster AB, Jarman M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isaphosphamide. Biochemical Pharmacology 23: 115–129, 1974

    Article  Google Scholar 

  • Cooper KR, Hong WK. Prospective study of pulmonary toxicity of continuously infused bleomycin. Cancer Treatment Reports 65: 419–425, 1981

    PubMed  CAS  Google Scholar 

  • Creasey WA, Mcintosh LS, Brescia T, Odujinrin O, Aspnes GT, et al. Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. Cancer Research 36: 216–221, 1976

    PubMed  CAS  Google Scholar 

  • Creaven PJ. The clinical pharmacology of VM26 and VP16-213: a brief overview. Cancer Chemotherapy and Pharmacology 7: 133–140, 1982

    Article  PubMed  CAS  Google Scholar 

  • Creaven PJ, Allen LM. EPEG, a new antineoplastic epipodophyllotoxin. Clinical Pharmacology and Therapeutics 18: 221–226, 1975a

    PubMed  CAS  Google Scholar 

  • Creaven PJ, Allen LM. PTG, a new antineoplastic epipodophyllotoxin. Clinical Pharmacology and Therapeutics 18: 227–233, 1975b

    PubMed  CAS  Google Scholar 

  • Creaven PJ, Hansen HH, Alford DA, et al. Methotrexate in liver and bile after intravenous dosage in man. British Journal of Cancer 28: 589–591, 1973

    Article  PubMed  CAS  Google Scholar 

  • Crom WR. Doxorubicin. In Taylor & Diers (Eds) Textbook for the clinical application of therapeutic drug monitoring, pp. 421–429, Abbott Laboratories, Diagnostic Division, Irving, 1986

    Google Scholar 

  • Crom W, Mauer E, Greene W, McHaney V, Hayes F, et al. Relation between cisplatin ototoxicity and platinum accumulation in plasma. (Abstract.) Proceedings of the American Society of Clinical Oncology 3: 28, 1984a

    Google Scholar 

  • Crom WR, Evans WE, Pratt CB, Senzer N, Denison M, et al. Cisplatin disposition in children and adolescents with cancer. Cancer Chemotherapy and Pharmacology 6: 95–99, 1981

    Article  PubMed  CAS  Google Scholar 

  • Crom WR, Pratt CB, Green AA, et al. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. Journal of Clinical Oncology 2: 655–661, 1984b

    PubMed  CAS  Google Scholar 

  • Crom WR, Riley CA, Green AA, Hayes FA, Pratt CB, et al. Doxorubicin disposition in children and adolescents with cancer. (Abstract.) Drug Intelligence and Clinical Pharmacy 17: 448, 1983

    Google Scholar 

  • Crom WR, Kalwinsky D, Glynn AM, Evans WE. Clearance of etoposide during continuous 72-hour intravenous infusion in children. (Abstract.) Drug Intelligence and Clinical Pharmacy 20: 472, 1986

    Google Scholar 

  • Crooke ST, Comis RL, Einhorn LH, Strong JE, Broughton A, et al. Effects of variations in renal function on the clinical pharmacology of bleomycin administered as an IV bolus. Cancer Treatment Reports 61: 1631–1636, 1977

    PubMed  CAS  Google Scholar 

  • Cvitkovic E, Spaulding J, Bethune V, Martin J, Whitmore WF. Improvement of cis-dichlorodiammineplatinum (NSC 119875): therapeutic index in an animal model. Cancer 39: 1357–1361, 1977

    Article  PubMed  CAS  Google Scholar 

  • Davis HL, Davis TE. Daunorubicin and adriamycin in cancer treatment: an analysis of their roles and limitations. Cancer Treatment Reports 63(5): 809–815, 1979

    PubMed  CAS  Google Scholar 

  • DeConti RC, Toftness BR, Lange RC, Creasey WA. Clinical and pharmacological studies with cis-dichlorodiammineplatinum (II). Cancer Research 33: 1310–1315, 1973

    PubMed  CAS  Google Scholar 

  • Desai ZR, Van den Berg HW, Bridges JM, Shands RG. Can severe vincristine neurotoxicity be prevented? Cancer Chemotherapy Pharmacology 8: 211–214, 1982

    Article  CAS  Google Scholar 

  • Dinarello CA, Ward SB, Wolff SM. Pyrogenic properties of bleomycin (NSC-125066). Cancer Chemotherapy Reports 57: 393–398, 1973

    CAS  Google Scholar 

  • D’Incalci M, Balis G, Facchinetti T, Mangioni C, Morasca L, et al. Decreased half-life of cyclophosphamide in patients under continual treatment. European Journal of Cancer 19: 7–10, 1979

    Google Scholar 

  • D’Incalci M, Farina P, Sessa C, Mangioni C, Conter V, et al. Pharmacokinetics of VP16-213 given by different administration methods. Cancer Chemotherapy and Pharmacology 7: 141–145, 1982a

    PubMed  Google Scholar 

  • D’Incalci M, Garattini S. Podophyllotoxin derivatives VP-16 and VM-26. In Pinedo & Chabner (Eds) Cancer chemotherapy 7, pp. 98–104, Elsevier Science Publishers B.V., New York, 1985

    Google Scholar 

  • D’Incalci M, Rossi C, Sessa C, Urso R, Zucchetti M, et al. Pharmacokinetics of teniposide in patients with ovarian cancer. Cancer Treatment Reports 69: 73–77, 1985a

    PubMed  Google Scholar 

  • D’Incalci M, Rossi C, Zucchetti M, Urso R, Cavalli F, et al. Pharmacokinetics of etoposide in patients with abnormal renal and hepatic function. Cancer Research 46: 2566–2571, 1986

    PubMed  Google Scholar 

  • D’Incalci M, Sessa C, Farina P, Rossi C, Beer M, et al. Clinical pharmacokinetics of VP-16. 73rd Proceedings of American Association of Cancer Research, St. Louis, Missouri, April 28–May 1, 23: 131, (C-516), 1982b

    Google Scholar 

  • D’Incalci M, Sessa C, Rossi C, Roviaro G, Mangioni C. Pharmacokinetics of etoposide in gestochoriocarcinoma. Cancer Treatment Reports 69: 69–72, 1985b

    PubMed  Google Scholar 

  • Dixon RL, Henderson ES, Rail DP. Plasma protein binding of methotrexate and its displacement by various drugs. Federal Proceedings 24: 454, 1965

    Google Scholar 

  • Dombernowsky D, Nissen NI. Combination chemotherapy with 4′demethylepipodophyllotoxin-9-(4,6-0-ethylidine-↔-D-gluco-pyranoside) VP-16-213 (NSC141540), in L1210 leukemia. European Journal of Cancer 12: 181–188, 1976

    Article  PubMed  CAS  Google Scholar 

  • Donehower RC, Hande KR, Drake JC, et al. Presence of 2,4 diamino-Nl0-methylpteroic acid after high-dose methotrexate. Clinical Pharmacology and Therapeutics 26: 63–72, 1979

    PubMed  CAS  Google Scholar 

  • Dow LW, Sinkule JA, Look AT, Horvath A, Evans WE. Comparative cytotoxic and cytokinetic effects of the epipodophyllotoxins 4′-demethylepipodophyllotoxin-9-(4,6-0-2-ethylidene-β-D-glucopyranoside) and 4′-demethylepipodophyllotoxin-9-(4,6-0-2-thenylidene-β-D-glucopyranoside) and their metabolites on human leukemic lymphoblasts. Cancer Research 43: 5699–5706, 1983

    PubMed  CAS  Google Scholar 

  • Dumas M, D’Athis P, de Gislain C, Escousse A, Guerrin J, et al. Model independent pharmacokinetic study of cis-dichlorodiammineplatinum (II). International Journal of Clinical Pharmacology, Therapy, and Toxicology 23: 430–433, 1985

    PubMed  CAS  Google Scholar 

  • Duncan JH, Colvin MD, Fenselau C. Mass spectrometric study of the distribution of cyclophosphamide in humans. Toxicology and Applied Pharmacology 24: 317–323, 1973

    Article  PubMed  CAS  Google Scholar 

  • Egan PC, Costanza ME, Dodion P, Egorin MJ, Bachur NR. Doxorubicin and cisplatin excretion into human milk. Cancer Treatment Reports 69(12): 1387–1389, 1985

    PubMed  CAS  Google Scholar 

  • Egorin MJ, Van Echo DA, Olman EA, Whitacre MY, Forrest A, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum (II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Research 45: 6502–6506, 1985

    PubMed  CAS  Google Scholar 

  • Egorin MJ, Van Echo DA, Tipping SJ, Olman EA, Whitacre MY, et al. Pharmacokinetics and dosage reduction of cis-diammine (1, 1-cyclobutane-dicarboxylate) platinum in patients with impaired renal function. Cancer Research 44: 5432–5438, 1984

    PubMed  CAS  Google Scholar 

  • Eksborg S, Ehrsson H, Ekqvist B. Protein binding of anthraquinone glycosides with special reference to adriamycin. Cancer Chemotherapy and Pharmacology 10: 7–10, 1982

    Article  PubMed  CAS  Google Scholar 

  • Erttmann R, Bielack S, Landbuck G. Kinetics of 7-hydroxy-methotrexate after high-dose methotrexate therapy. Cancer Chemotherapy and Pharmacology 15: 101–104, 1985

    Article  PubMed  CAS  Google Scholar 

  • European Organisation for Research on the Treatment of Cancer, Clinical Screening Group. Epipodophyllotoxin VP16213 in treatment of acute leukemias, haematosarcomas and solid tumours. British Medical Journal 3: 199–202, 1973

    Article  Google Scholar 

  • Evans AE, Baehner RL, Chard Jr RL, Leikin SL, Pang EM, et al. Comparison of daunorubicin (NSC-83142) with adriamycin (NSC-123127) in the treatment of late-stage childhood solid tumors. Cancer Chemotherapy Reports 58(5): 671–676, 1974

    CAS  Google Scholar 

  • Evans WE, Crom WR, Abromowitch M, Dodge R, Look AT, et al. Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. New England Journal of Medicine 314: 471–477, 1986a

    Article  PubMed  CAS  Google Scholar 

  • Evans WE, Crom WR, Green AA, Hayes FA, Pratt CB. Cis-diamminedichloride platinum disposition in children: parameters of a multi-compartment kinetic model. In Nelson & Grassi (Eds) Current chemotherapy and infectious disease, pp. 1508–1510, American Society for Microbiology, Washington, DC, 1980a

    Google Scholar 

  • Evans WE, Crom WR, Stewart CF, Bowman WP, Chen CH, et al. Methotrexate systemic clearance influences probability of relapse in children with standard-risk acute lymphocytic leukemia. Lancet 1: 359–362, 1984

    Article  PubMed  CAS  Google Scholar 

  • Evans WE, Crom WR, Tsiatis A, Green AA, Hayes FA, et al. Pharmacokinetic modeling of cisplatin disposition in children and adolescents with cancer. Cancer Chemotherapy and Pharmacology 10: 22–26, 1982c

    Article  PubMed  CAS  Google Scholar 

  • Evans WE, Crom WR, Yalowich JC. Methotrexate. In Evans et al. (Eds) Applied pharmacokinetics, pp. 1009–1056, Applied Therapeutics, Inc., San Francisco, 1986b

    Google Scholar 

  • Evans WE, Crom WR, Yee GC. Adriamycin pharmacokinetics in children. Proceedings of American Association of Cancer Research and American Association of Clinical Oncology. Abstract, p. 176, 1980b

  • Evans WE, Hutson PR, Stewart CF, et al. Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion. Clinical Pharmacology and Therapeutics 33: 301–307, 1983a

    Article  PubMed  CAS  Google Scholar 

  • Evans WE, Crom WR, Sinkule JA, Yee GC, Stewart CF, Hutson PR. Pharmacokinetics of anticancer drugs in children. Drug Metabolism Reviews 14: 847–886, 1983b

    Article  PubMed  CAS  Google Scholar 

  • Evans WE, Pratt CB. Effect of pleural effusion on high-dose methotrexate kinetics. Clinical Pharmacology and Therapeutics 23: 68–72, 1978

    PubMed  CAS  Google Scholar 

  • Evans WE, Pratt CB, Taylor RH, et al. Pharmacokinetic monitoring of high-dose methotrexate: early recognition of high-risk patients. Cancer Chemotherapy and Pharmacology 3: 161–166, 1979

    Article  PubMed  CAS  Google Scholar 

  • Evans WE, Sinkule JA, Crom WR, Dow L, Look AT, et al. Pharmacokinetics of teniposide (VM26) and etoposide (VP16-213) in children with cancer. Cancer Chemotherapy and Pharmacology 7: 147–150, 1982a

    Article  PubMed  CAS  Google Scholar 

  • Evans WE, Sinkule JA, Horvath A, Crom WR, Dow LW, et al. Clinical pharmacology of VM-26 [NSC 122819] and VP-16-213 [NSC 141540] in children with cancer. 72nd Proceedings of the American Association of Cancer Research, Washington, D.C., April 27–30, 22: 174 (690), 1981a

  • Evans WE, Stewart CF, Hutson PR, et al. Disposition of intermediate dose methotrexate in children with ALL. Drug Intelligence and Clinical Pharmacy 16: 839–842, 1982b

    PubMed  CAS  Google Scholar 

  • Evans WE, Tsiatis A, Crom WR, et al. Pharmacokinetics of sustained serum methotrexate concentrations secondary to gastrointestinal obstruction. Journal of Pharmaceutical Sciences 70: 1194–1198, 1981b

    Article  PubMed  CAS  Google Scholar 

  • Exelby PR. Testis cancer in children. Seminars in Oncology 6: 116–120, 1979

    PubMed  CAS  Google Scholar 

  • Fabre G, Matherly LH, Fabre I, et al. Interactions between 7-hydroxymethotrexate and methotrexate at the cellular level in the Ehrlich ascites tumor in vitro. Cancer Research 44: 970–975, 1984

    PubMed  CAS  Google Scholar 

  • Fabre G, Matherly LH, Fabre I, et al. In vitro formation of polyglutamyl derivatives of methotrexate and 7-hydromethotrexate in human lymphoblastic leukemia cells. Cancer Research 43: 4648–4652, 1983

    PubMed  CAS  Google Scholar 

  • Fabre I, Fabre G, Goldman ID. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Research 44: 3190–3195, 1984

    PubMed  CAS  Google Scholar 

  • Farquhar D, Loo TL. Synthesis and biologic evaluation of 7-hydroxymethotrexate, 7-methylaminopterin, and 7-methyl methotrexate. Journal of Clinical Chemistry 15: 567–570, 1972

    CAS  Google Scholar 

  • Fernbach DJ, Griffith KM, Haggard ME, et al. Chemotherapy of acute leukemia in childhood: comparison of cyclophosphamide and mercaptopurine. New England Journal of Medicine 275: 451–456, 1966

    Article  PubMed  CAS  Google Scholar 

  • Freeman MV. The fluorometric measurement of the absorption, distribution and excretion of single doses of 4-amino-10-methylpteroylglytamic acid (amethopterin) in man. Journal of Pharmacology and Experimental Therapeutics 122: 154–162, 1958

    PubMed  CAS  Google Scholar 

  • Freeman-Narrod M, Gerstley BJ, Engstrom PH, et al. Comparison of serum concentrations of methotrexate after various routes of administration. Cancer 36: 1619–1624, 1975

    Article  PubMed  CAS  Google Scholar 

  • Frei III E, Spurr CL, Brindley CO, et al. Clinical studies of dichloromethotrexate (NSC 29630). Clinical Pharmacology and Therapeutics 6: 160–171, 1965

    PubMed  CAS  Google Scholar 

  • Frick GA, Ballentine R, Driever CW, Kramer W. Renal excretion kinetics of high-dose cis-dichlorodiammineplatinum (II) administered with hydration and mannitol diuresis. Cancer Treatment Reports 63: 13–16, 1979

    PubMed  CAS  Google Scholar 

  • Fry DW, Anderson LA, Borst M, et al. Analysis of the role of membrane transport and polyglutamation of methotrexatein gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. Cancer Research 43: 1087–1092, 1983

    PubMed  CAS  Google Scholar 

  • Fujita H. Comparative studies on the blood level, tissue distribution, excretion and inactivation of anticancer drugs. Japanese Journal of Clinical Oncology 12: 151–162, 1971

    Google Scholar 

  • George CRP. Non-specific enhancement of glomerular filtration by corticosteroids. Lancet 2: 728, 1974

    Article  PubMed  CAS  Google Scholar 

  • Ginsberg SJ, Comis RL. The pulmonary toxicity of antineoplastic agents. In Perry & Yarbro (Eds) Toxicity of chemotherapy, pp. 227–268, Grune and Stratton, Inc., New York, 1984

    Google Scholar 

  • Goldie JH, Price LA, Harrap KR. Methotrexate toxicity: correlation with duration of administration, plasma levels, dose and excretion pattern. European Journal of Cancer 8: 409–414, 1972

    Article  PubMed  CAS  Google Scholar 

  • Goldman ID, Gupta V, White JC, et al. Exchangeable intracellular methotrexate levels in the presence and absence of vincristine at extracellular drug concentrations relevant to those achieved in high-dose methotrexate-folinic acid rescue protocols. Cancer Research 36: 276–279, 1976

    PubMed  CAS  Google Scholar 

  • Gormley PE, Bull JM, LeRoy AF, Cysyk R. Kinetics of cis-dichlorodiammineplatinum. Clinical Pharmacology and Therapeutics 25: 351–357, 1979

    PubMed  CAS  Google Scholar 

  • Gormley P, Gangji D, Wood JH, Poplack DG. Pharmacokinetic study of cerebrospinal fluid penetration of cis-diamminedi-chloroplatinum (II). Cancer Chemotherapy and Pharmacology 5: 247–260, 1981

    Article  Google Scholar 

  • Greene RF, Collins JM, Jenkins JF, Speyer JL, Myers LE. Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols. Cancer Research 43: 3417–3421, 1983

    PubMed  CAS  Google Scholar 

  • Gullo JJ, Litterst CL, Maguire PJ, Sikic BI, Hoth DF, et al. Pharmacokinetics and protein binding of cis-dichlorodiammine platinum (II) administered as a one hour or as a twenty hour infusion. Cancer Chemotherapy and Pharmacology 5: 21–26, 1980

    Article  PubMed  CAS  Google Scholar 

  • Haas CD, Coltman CA, Gottlieb JA, Hart A, Luce JK, et al. Phase II evaluation of bleomycin: a Southwest Oncology Group Study. Cancer 38: 8–12, 1976

    Article  PubMed  CAS  Google Scholar 

  • Haidle CW, Weiss KK, Kuo MT. Release of free bases from deoxyribonucleic acid after reaction with bleomycin. Molecular Pharmacology 8: 531–537, 1972

    PubMed  CAS  Google Scholar 

  • Hande KR, Wedlund PJ, Noone RM, Wilkinson GR, Greco FA, et al. Pharmacokinetics of high-dose etoposide (VP-16-213) administered to cancer patients. Cancer Research 44: 379–382, 1984

    PubMed  CAS  Google Scholar 

  • Harvey VJ, Slevin ML, Joel SP, Barnett MJ, Smythe MM. The pharmacokinetics of oral etoposide (VP-16-213). Proceedings of the American Society of Clinical Oncology, Toronto, May 6–8, 30: 24 (90), 1984a

    Google Scholar 

  • Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PFM. The effect of dose on the bioavailability of oral etoposide. Cancer Chemotherapy and Pharmacology 16: 178–181, 1986

    Article  PubMed  CAS  Google Scholar 

  • Harvey VJ, Slevin ML, Joel SP, Johnston A, Wrigley PFM. The effect of food and concurrent chemotherapy on the bioavailability of oral etoposide. British Journal of Cancer 52: 363–367, 1985a

    Article  PubMed  CAS  Google Scholar 

  • Harvey VJ, Slevin ML, Joel SP, Smythe MM, Johnston A, et al. Variable bioavailability following repeated oral doses of etoposide. European Journal of Cancer and Clinical Oncology 21: 1315–1319, 1985b

    Article  CAS  Google Scholar 

  • Harvey VJ, Slevin ML, Woolland RC, et al. The bioavailability of oral intermediate-dose methotrexate. Cancer Chemotherapy and Pharmacology 13: 91–94, 1984b

    Article  PubMed  CAS  Google Scholar 

  • Hayes FA, Green AA, Casper J, et al. Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma. Cancer 48: 1715–1718, 1981

    Article  PubMed  CAS  Google Scholar 

  • Hendel J, Nyfors A. Nonlinear renal elimination kinetics of methotrexate due to saturation of renal tubular reabsorption. European Journal of Clinical Pharmacology 26: 121–124, 1984

    Article  PubMed  CAS  Google Scholar 

  • Henderson ES, Adamson RH, Oliverio VT. The metabolic fate of tritiated methotrexate II, absorption and excretion in man. Cancer Research 25: 1018–1024, 1985

    Google Scholar 

  • Higby DJ, Buchholtz L, Chary K, Avellanosa A, Henderson ES. Kinetics of cisplatin (DDP) with intensive diuresis. Proceedings of the American Association for Cancer Research 18: 110, 1977

    Google Scholar 

  • Hill JM, Loeb E, MacLellan A, Hill NO, Khan A, et al. Clinical studies of platinum coordination compounds in the treatment of various malignant diseases. Cancer Chemotherapy Reports 59: 647–659, 1975

    CAS  Google Scholar 

  • Himmelstein KJ, Patton TF, Belt RJ, Taylor S, Repta AJ, et al. Clinical kinetics of intact cisplatin and some related species. Clinical Pharmacology and Therapeutics 29: 658–664, 1981

    Article  PubMed  CAS  Google Scholar 

  • Hiyniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. Journal of Clinical Oncology 2: 1281–1288, 1984

    Google Scholar 

  • Ho DHW, Kanellopoulos KA, Yap HY, Casimir M, Savaraj N, et al. Clinical pharmacology of etoposide by radioimmunoassay. Proceedings of the American Association of Cancer Research 519: 131, 1983

    Google Scholar 

  • Holthuis JJM, Van de Vyver FL, van Oort WJ, Verleun H, Bekaert AB, et al. Pharmacokinetic evaluation of increasing dosages of etoposide in a chronic hemodialysis patient. Cancer Treatment Reports 69: 1279–1282, 1985

    PubMed  CAS  Google Scholar 

  • Huffman DH, Bachur NR. Daunorubicin metabolism in acute myelocytic leukemia. Blood 39: 637–643, 1972

    PubMed  CAS  Google Scholar 

  • Huffman DH, Wan SH, Azarnoff DL, et al. Pharmacokinetics of methotrexate. Clinical Pharmacology and Therapeutics 14: 572–579, 1973

    PubMed  CAS  Google Scholar 

  • Hulhoven R, Sokal G, Harvengt C. Human pharmacokinetics of the daunorubicin-DNA complex. Cancer Chemotherapy and Pharmacology 3: 243–247, 1979

    PubMed  CAS  Google Scholar 

  • Isacoff WH, Morrison PF, Aroesty J, et al. Pharmacokinetics of high-dose methotrexate with citrovorum factor rescue. Cancer Treatment Reports 61: 1665–1674, 1977

    PubMed  CAS  Google Scholar 

  • Isacoff WH, Townsend CT, Eliber FR, et al. High-dose methotrexate therapy of solid tumors: observations relating to clinical toxicity. Medical Pediatric Oncology 2: 319–325, 1976

    Article  CAS  Google Scholar 

  • Issell BF. The podophyllotoxin derivatives VP16-213 and VM-26. Cancer Chemotherapy and Pharmacology 7: 73–80, 1982

    PubMed  CAS  Google Scholar 

  • Ivey FJ, Amend WJZ, Lozada F, Frey BM, Holford NHG, et al. Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients. European Journal of Clinical Pharmacology 21: 235–242, 1981

    Article  Google Scholar 

  • Jackson DV, Bender RA. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro. Cancer Research 39: 4346–4349, 1979

    PubMed  CAS  Google Scholar 

  • Jackson DV, Castle ML, Bender RA. Biliary excretion of vincristine. Clinical Pharmacology and Therapeutics 24: 101–107, 1978

    PubMed  Google Scholar 

  • Jackson DV, Chavnenet AR, Callahan RD, Atkins JM, Trahey TF, et al. Phase II trial of vincristine infusion in acute leukemia. Cancer Chemotherapy and Pharmacology 14: 26–29, 1985

    Article  PubMed  Google Scholar 

  • Jackson DV, Sethie VS, Spurr CL, White DR, Richards F, et al. Pharmacokinetics of vincristine infusion. Cancer Treatment Reports 65: 1043–1048, 1981

    PubMed  Google Scholar 

  • Jao JY, Jusko WJ, Cohen JL. Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Research 32: 2761–2764, 1972

    PubMed  CAS  Google Scholar 

  • Jardine I, Fenselan C, Appler M, Kan MN, Brundrett RB, Colvin M. Quantitation by gas chromatography-chemical ionization mass spectrometry of cyclophosphamide, phosphoramide mustard, and nornitrogen mustard in the plasma and urine of patients receiving cyclophosphamide therapy. Cancer Research 38: 408–415, 1978

    PubMed  CAS  Google Scholar 

  • Johns DG, Valerino DM. Metabolism of folate antagonists. American New York Academy of Science 196: 378–386, 1971

    Article  Google Scholar 

  • Jolivet J, Cowan KH, Curt GA, Chabner BA. The pharmacology and clinical use of methotrexate. New England Journal of Medicine 309: 1094–1104, 1983

    Article  PubMed  CAS  Google Scholar 

  • Jolivet J, Schilsky RL, Bailey BD, et al. Synthesis, retention, and biological activity of methotrexate polyglutamates in cultured human breast cancer cells. Journal of Clinical Investigations 70: 351–360, 1982

    Article  CAS  Google Scholar 

  • Jones B, Holland JF, Glidewell O, Jacquillat C, Weil M, et al. Optimal use of L-asparaginase (NSC-109229) in acute lymphocytic leukemia. Medical Pediatric Oncology 3: 387–400, 1977

    Article  CAS  Google Scholar 

  • Jones B, Shuster JJ, Holland JF. Lower incidence of meningeal leukemia when dexamethasone is substituted for prednisone in the treatment of acute lymphocytic leukemia — a late follow-up. (Abstract 191.) American Society of Clinical Oncology, 1984

    Google Scholar 

  • Juma FD, Rogers HJ, Trounce JR. Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. British Journal of Clinical Pharmacology 8: 209–217, 1979

    Article  PubMed  CAS  Google Scholar 

  • Juma FD, Rogers HJ, Trounce JR. The pharmacokinetics of cyclophosphamide, phosphoramide mustard and nor-nitrogen mustard studied by gas chromatography in patients receiving cyclophosphamide therapy. British Journal of Clinical Pharmacology 10: 327–335, 1980

    PubMed  CAS  Google Scholar 

  • Kalwinsky D. Combined continuous infusions of etoposide (VP-16) and cytarabine (ARA-C) in childhood acute myelogenous leukemia (AML): clinical and pharmacologic effects. (Abstract.) In Childhood tumors: multidisciplinary approach to sarcomas, 19th Annual Clinical Symposium, St Jude Children’s Research Hospital, February 22–23, 1985

  • Kalwinsky DK, Look AT, Ducore J, Fridland A. Effects of the epipodophyllotoxin VP-16-213 on cell cycle traverse, DNA synthesis, and DNA strand size in cultures of human leukemia lymphoblasts. Cancer Research 43: 1592–1597, 1983

    PubMed  CAS  Google Scholar 

  • Karp Gl, von Oeyen P, Valone F, Khetarpal VK, Israel M, et al. Doxorubicin in pregnancy: possible transplacental passage. Cancer Treatment Reports 67(9): 773–777, 1983

    PubMed  CAS  Google Scholar 

  • Kerr IG, Jolivet J, Collins JM, Drake JC, Chabner BA. Test dose for predicting high-dose methotrexate infusions. Clinical Pharmacology and Therapeutics 33: 44–51, 1983

    Article  PubMed  CAS  Google Scholar 

  • Kozower M, Veatch L, Kaplan MM. Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects. Journal of Clinical Endocrinology Metabolism 38: 407–412, 1974

    Article  PubMed  CAS  Google Scholar 

  • Krakoff IH, Cvitkovic E, Curie V, Yeh S, Lamonte C. Clinical pharmacologic and therapeutic studies of bleomycin given by continuous infusion. Cancer 40: 2027–2037, 1977

    Article  PubMed  CAS  Google Scholar 

  • Kramer WG, Feldman S, Broughton A, Strong JE, Hall SW, et al. The pharmacokinetics of bleomycin in man. Journal of Clinical Pharmacology 18: 346–352, 1978

    PubMed  CAS  Google Scholar 

  • Kristensen LO, Weisman K, Hutters L. Renal function and the role of disappearance of methotrexate from serum. European Journal of Clinical Pharmacology 8: 439–444, 1975

    Article  PubMed  CAS  Google Scholar 

  • Lange RC, Spencer RP, Harder HC. The antitumor agent cis-Pt(NH3)2Cl2; distribution studies and dose calculations for 193mPt and l95mPt. Journal of Nuclear Medicine 14: 191–195, 1973

    PubMed  CAS  Google Scholar 

  • Lankelma J, vanderKlein E, Ramaekers F. The role of 7-hydrox-ymethotrexate during methotrexate anti-cancer therapy. Cancer Letters 9: 133–142, 1980

    Article  PubMed  CAS  Google Scholar 

  • Lee YN, Chan KK, Harris PA, Cohen JL, et al. Distribution of adriamycin in cancer patients. Cancer 45: 2231–2239, 1980

    Article  PubMed  CAS  Google Scholar 

  • Legha SS, Benjamin RS, Mackay B, Ewer M, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusions. Annals of Internal Medicine 96(2): 133–139, 1982

    PubMed  CAS  Google Scholar 

  • Legha SS. Vincristine neurotoxicity: pathophysiology and management. Medical Toxicology 1: 421–427, 1986

    PubMed  CAS  Google Scholar 

  • Lerne PR, Creaven PF, Allen LM, et al. Kinetic model for the disposition and metabolism of moderate and high-dose methotrexate (NSC-740) in man. Cancer Chemotherapy Reports 59: 811–817, 1975

    Google Scholar 

  • LeRoy AF, Wehling M, Gormley P, Egorin M, Ostrow S, et al. Quantitative changes in cis-dichlorodiammineplatinum (II) speciation in excreted urine with time after IV infusion in man: methods of analysis, preliminary studies, and clinical results. Cancer Treatment Reports 64: 123–132, 1980

    PubMed  CAS  Google Scholar 

  • Levitt M, Mosher MS, Deconti RC. Improved therapeutic index of methotrexate with ‘leucovorin rescue’. Cancer Research 33: 1729–1734, 1973

    PubMed  CAS  Google Scholar 

  • Lewis GP, Jusko WJ, Burke CW, Graves L. Prednisone side-effects and serum protein levels. Lancet 2: 778–785, 1971

    Article  PubMed  CAS  Google Scholar 

  • Liegler DG, Henderson ES, Hahn MA, et al. The effect of organic acid on renal clearance of methotrexate in man. Clinical Pharmacology and Therapeutics 10: 849–857, 1969

    PubMed  CAS  Google Scholar 

  • Lippard SJ. New chemistry of an old molecule: cis-[Pt(NH3)2Cl2]. Science 218: 1075–1082, 1982

    Article  PubMed  CAS  Google Scholar 

  • Litterst CL, Gram TE, Dedrick RL, Leroy AF, Guarino AM. Distribution and disposition of platinum following intravenous administration of cis-dichlorodiammineplatinum (II) (NSC 119875) to dogs. Cancer Research 36: 2340–2344, 1976

    PubMed  CAS  Google Scholar 

  • Loehrer PJ, Einhorn LD. Cisplatin. Annals of Internal Medicine 100: 704–713, 1984

    PubMed  CAS  Google Scholar 

  • Loike JD, Horwitz SB. Effect of VP16-213 on the intracellular degradation of DNA in hela cells. Biochemistry 15: 5443–5448, 1976

    Article  PubMed  CAS  Google Scholar 

  • Lokich J, Bothe A, Zipoli T, Green R, et al. Constant infusion schedule for adriamycin: a Phase I-II clinical trial of a 30-day schedule by ambulatory pump delivery system. Journal of Clinical Oncology 1: 24–28, 1983

    PubMed  CAS  Google Scholar 

  • Long BH, Musial ST, Brattain MG. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. Biochemistry 23: 1183–1188, 1984

    Article  PubMed  CAS  Google Scholar 

  • Long DF, Repta AJ. Cisplatin: chemistry, distribution, and biotransformation. Biopharmaceutics and Drug Disposition 2: 1–16, 1981

    Article  CAS  Google Scholar 

  • Loo TL, Hall SW, Salem P, Benjamin RS, Lu K. Clinical pharmacological and toxicological studies of cis-diamminedichloroplatinum (II) by continuous intravenous infusion. Biochimie 60: 957–960, 1978

    Article  CAS  Google Scholar 

  • Marsh W, Center MS. Evidence for the involvement of two distinct membrane proteins in adriamycin resistance in Chinese hamster lung cells. Cancer Research 45: 6088–6092, 1985

    PubMed  CAS  Google Scholar 

  • Matherly LH, Barlowe CK, Banks WL, Goldman ID. Polyglutamylation of 2,4-diaminoantifolates as a critical determinant of leucovorin rescue. (Abstract.) American Association of Clinical Research Proceedings 26: 233, 1985

    Google Scholar 

  • McGuire JJ, Hsieh P, Coward JK, et al. Enzymatic synthesis of folylpolyglutamates: characterization of the reaction and its products. Journal of Biological Chemistry 255: 5776–5788, 1981

    Google Scholar 

  • McHaney VA, Thibadoux MA, Hayes FA, Green AA. Hearing loss in children receiving cisplatin chemotherapy. Journal of Pediatrics 102: 314–317, 1983

    Article  PubMed  CAS  Google Scholar 

  • Meikle AW, Week JA, Tyler FH. Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunoassays. Journal of Clinical Endocrinology Metabolism 41: 717–721, 1975

    Article  PubMed  CAS  Google Scholar 

  • Milano G, Thyss A, Renee N, et al. Plasma levels of 7-hydroxymethotrexate after high-dose methotrexate treatment. Cancer Chemotherapy and Pharmacology 11: 29–32, 1983

    Article  PubMed  CAS  Google Scholar 

  • Minow RA, Benjamin RS, Gottlieb JA. Adriamycin (NSC-123127) cardiomyopathy: an overview with determination of risk factors. Cancer Chemotherapy Reports 6(2): 195–201, 1975

    Google Scholar 

  • Mosende C, Guttierez M, Caparros B, Rosen G. Combination chemotherapy with bleomycin cyclophosphamide, and dactinomycin for the treatment of osteogenic sarcoma. Cancer 40: 2779–2786, 1977

    Article  PubMed  CAS  Google Scholar 

  • Muller WEG, Yamazaki Z, Breter H, Zahn RK. Action of bleomycin on DNA and RNA. European Journal of Biochemistry 31: 518–525, 1972

    Article  PubMed  CAS  Google Scholar 

  • Myers C, Muindi J, Batist G, Haim N, Sinha BK, et al. Anthracyclines. In Pinedo & Chabner (Eds) Cancer chemotherapy 7, pp. 57–75, Elsevier Science Publishers B.V., New York, 1985

    Google Scholar 

  • Nanji AA, Mikhael NZ, Stewart DJ. Hypoalbuminemia in patients receiving cisplatin: correlation between liver platinum and decrease in serum albumin. Oncology 43: 33–35, 1986

    Article  PubMed  CAS  Google Scholar 

  • Nelson RL, Dyke RW, Root MA. Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treatment Reviews 7: 17–24, 1980

    Article  PubMed  Google Scholar 

  • Nierenberg DW, Mamelok RD. Toxic reaction to methotrexate in a patient receiving penicillin and furosemide: a possible interaction. Archives of Dermatology 119: 449–450, 1983

    Article  PubMed  CAS  Google Scholar 

  • Nilsson S, Andersson B, Eksborg S, Beran M, Ehrsson H. Pharmacokinetics of daunorubicin after administration as free drug or as DNA complex in leukemic patients. Cancer Chemotherapy and Pharmacology 5: 261–266, 1981

    Article  PubMed  CAS  Google Scholar 

  • Nirenberg A, Mosende C, Mehta BM, et al. High dose methotrexate with CF rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. Cancer Treatment Reports 61: 779–783, 1977

    PubMed  CAS  Google Scholar 

  • O’Dwyer PJ, Leyland-Jones B, Alonso MT, Marsoni S, Wittes RE. Etoposide (VP-16-213) current status of an active anticancer drug. New England Journal of Medicine 312: 692–700, 1985

    Article  PubMed  Google Scholar 

  • Ohnuma T, Holland JF, Masuda H, et al. Microbiological assay of bleomycin: inactivation, tissue distribution and clearance. Cancer 33: 1230–1238, 1974

    Article  Google Scholar 

  • Oosterbaan MJM, Dirks MJM, Vree TB, et al. Klinische farmacokinetische vanadriamycin. Journal of Drug Research 7: 1372–1378, 1982

    Google Scholar 

  • Owellen RJ, Hartke CA, Hains FO. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Research 37: 2597–2602, 1977

    PubMed  CAS  Google Scholar 

  • Patton TF, Himmelstein KJ, Belt R, Bannister SJ, Sternson LA, et al. Plasma levels and urinary excretion of filterable platinum species following bolus injection and IV infusion of cis-dichlorodiammineplatinum (II) in man. Cancer Treatment Reports 62: 1359–1362, 1978

    PubMed  CAS  Google Scholar 

  • Patton TF, Repta AJ, Sternson LA, Belt RJ. Pharmacokinetics of intact cisplatin in plasma infusion versus bolus dosing. International Journal of Pharmaceutics 10: 77–85, 1982

    Article  CAS  Google Scholar 

  • Paxton JW. Interaction of probenecid with the protein binding of methotrexate. Pharmacology 28: 86–89, 1984

    Article  PubMed  CAS  Google Scholar 

  • Pelsor FR, Allen LM, Creaven PJ. Multicompartment pharmacokinetic model of 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside) in humans. Journal of Pharmaceutical Sciences 67: 1106–1108, 1978

    Article  PubMed  CAS  Google Scholar 

  • Peng Y-M, Alberts DS, Lim HD. High performance liquid chromatographic analysis of vinzolidine (VZD) and related vinca alkaloids in biological samples. Proceedings of the American Association of Clinical Research 27: 407, 1986

    Google Scholar 

  • Pfeffer M, Nardella PA, Van Harken DR, Smyth RD, Issell BF, et al. The absolute bioavailability and pharmacokinetics of etoposide. In Issell et al. (Eds) Etoposide (VP-16) current status and new developments, pp. 127–140, Academic Press Inc., Orlando, 1984

    Google Scholar 

  • Piel JJ, Rayadu GVS, Perlia CP, Friedman AM, Fordham EW. Use of neutron activation analysis to study excretion of cis-dichlorodiammineplatinum (DDP) in cancer patients. Proceedings of the American Association for Cancer Research 15: 111, 1974

    Google Scholar 

  • Pinedo HM, Chabner BA. Role of drug concentration, duration of exposure and endogenous metabolites in determining methotrexate cytotoxicity. Cancer Treatment Reports 61: 709–715, 1977

    PubMed  CAS  Google Scholar 

  • Pinkel D, Hernandez K, Borella L, et al. Drug dosage and remission duration in childhood lymphocytic leukemia. Cancer 27: 247–256, 1971

    Article  PubMed  CAS  Google Scholar 

  • Pinkerton CR, Glasgow JFT, Welchman SG, Bridges JM. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukemia? Lancet 11: 944–946, 1980

    Article  Google Scholar 

  • Pinkerton CR, Welshman SG, Kelly JG, Shanks RG, Bridges JM. Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology 10: 36–39, 1982

    Article  PubMed  CAS  Google Scholar 

  • Poser RG, Sirotnak FM, Chello PL. Differential synthesis of methotrexate polyglutamates in normal proliferative and neoplastic mouse tissue in vivo. Cancer Research 41: 4441–4446, 1981

    PubMed  CAS  Google Scholar 

  • Povirk LF. Catalytic release of deoxyribonucleic basis by oxidation and reduction of an iron bleomycin complex. Biochemistry 18: 3989–3995, 1979

    Article  PubMed  CAS  Google Scholar 

  • Pratt CB, Hayes A, Green AA, et al. Pharmacokinetic evaluation of cis-dichlorodiammineplatinum (II) in children with malignant solid tumors: a phase II study. Cancer Treatment Reports 65: 1021–1026, 1981

    PubMed  CAS  Google Scholar 

  • Pratt CB, Ransom JL, Evans WE. Age-related adriamycin cardiotoxicity in children. Cancer Treatment Reports 62(9): 1381–1385, 1978

    PubMed  CAS  Google Scholar 

  • Pratt CB, Robert D, Shanks EC, et al. Clinical trials and pharmacokinetics of intermittent high-dose methotrexate ‘leucovorin rescue’ for children with malignant tumors. Cancer Research 34: 3326–3331, 1974

    PubMed  CAS  Google Scholar 

  • Pratt CB, Howarth C, Evans WE, et al. High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcoma. Cancer Treatment Reports 64: 11–20, 1980

    PubMed  CAS  Google Scholar 

  • Prestayko AW, Crooke ST. Clinical pharmacology of bleomycin. In Carter et al. (Eds) Bleomycin: current status and new developments, pp. 117–130, Academic Press, New York, 1978

    Google Scholar 

  • Quddus FF, Leventhal BG, Boyett JM, Pullen DJ, Crist WM, et al. Glucocorticoid receptors in immunological subtypes of childhood acute lymphocytic leukemia cells: a Pediatric Oncology Group study. Cancer Research 45: 6482–6486, 1985

    PubMed  CAS  Google Scholar 

  • Rahman A, Ganjei A, Neefe JR. Comparative immunotoxicity of free doxorubicin and doxorubicin encapsulated in cardiolipin liposomes. Cancer Chemotherapy and Pharmacology 16: 28–34, 1986

    PubMed  CAS  Google Scholar 

  • Rechnitzer C, Scheibel E, Hendel J. Methotrexate in the plasma and cerebrospinal fluid of children treated with intermediate dose methotrexate. Acta Paediatrica Scandinavica 70: 615–618, 1981

    Article  PubMed  CAS  Google Scholar 

  • Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, et al. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treatment Reports 66: 19–23, 1982

    PubMed  CAS  Google Scholar 

  • Reece PA, Stafford I, Russell J, Gill PG. Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammine-platinum (II). Cancer Chemotherapy and Pharmacology 15: 295–299, 1985

    Article  PubMed  CAS  Google Scholar 

  • Rideout JM, Ayres DC, Lim CK, Peters TJ. Determination of etoposide (VP16-213) and teniposide (VM-26) in serum by high-performance liquid chromatography with electrochemical detection. Journal of Pharmaceutical and Biomedical Analysis 2: 125–128, 1984

    Article  PubMed  CAS  Google Scholar 

  • Riggs CE, Benjamin RS, Serpick AA, Bachur NR, et al. Biliary disposition of adriamycin. Clinical Pharmacology and Therapeutics 22(2): 234–241, 1977

    PubMed  Google Scholar 

  • Rivera G, Avery T, Pratt C. 4′demethylepipodophyllotoxin 9-(4,6-0-2-thenylidene-β-D-glucopyranoside) (NSC-122819; VM-26) and 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidine-β-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations. Cancer Chemotherapy Reports 59(4): 743–749, 1975

    CAS  Google Scholar 

  • Robert J, Hoerni B. Age dependence of the early-phase pharmacokinetics of doxorubicin. Cancer Research 43: 4467–4469, 1983

    PubMed  CAS  Google Scholar 

  • Robert J, Illiadis A, Hoerni B, et al. Pharmacokinetics of adriamycin in patients with breast cancer: correlation between pharmacokinetic parameters and clinical short-term response. European Journal of Cancer and Clinical Oncology 18: 739–745, 1982

    Article  CAS  Google Scholar 

  • Roberts JJ. Cisplatin. In Pinedo (Ed.) Cancer chemotherapy, pp. 95–117, Excerpta Medica, Amsterdam, 1982

    Google Scholar 

  • Rodman J, Abromowitch M, Sinkule J, Hayes FA, Rivera G, et al. Interpatient pharmacokinetic variability and systemic exposure as determinants of response to teniposide. Submitted for publication, 1986

  • Rose JQ, Nickelson JA, Ellis EF, Middleton E, Jusko WJ. Prednisolone disposition in steroid-dependent asthmatic children. Journal of Allergy and Clinical Immunology 67: 188–193, 1981a

    Article  PubMed  CAS  Google Scholar 

  • Rose JQ, Yurchak AM, Jusko WJ. Dose dependent pharmacokinetics of prednisone and prednisolone in man. Journal of Pharmacokinetics and Biopharmaceutics 9: 389–417, 1981b

    PubMed  CAS  Google Scholar 

  • Rose JQ, Yurchak AM, Jusko WJ, Powell D. Bioavailability and disposition of prednisone and prednisolone from oral prednisone tablets. Biopharmaceutics and Drug Disposition 1: 247–258, 1980

    Article  CAS  Google Scholar 

  • Rosen G, Marcove RC, Huvos AG, Caparros BI, Lane JM, et al. Primary osteogenic sarcoma: eight-year experience with adjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology 106 (Suppl.): 55–67, 1983

    Article  PubMed  Google Scholar 

  • Rosenberg B, Van Camp L, Krigos T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature 205: 698–699, 1965

    Article  PubMed  CAS  Google Scholar 

  • Rosenblatt DS, Whitehead VM, Vera N, et al. Prolonged inhibition of DNA synthesis associated with accumulation of methotrexate polyglutamates by cultured human cells. Molecular Pharmacology 14: 1143–1147, 1978

    PubMed  CAS  Google Scholar 

  • Ross W, Rowe T, Glisson B, Yalowich J, Liu L. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. Cancer Research 44: 5857–5860, 1984

    PubMed  CAS  Google Scholar 

  • Rossi C, Zucchetti M, Sessa C, Urso R, Mangioni C, et al. Pharmacokinetic study of VM-26 given as a prolonged IV infusion to ovarian cancer patients. Cancer Chemotherapy and Pharmacology 13: 211–214, 1984

    Article  PubMed  CAS  Google Scholar 

  • Rubin JS, Rubin RT. Cyclophosphamide hemorrhagic cystitis. Journal of Urology 96: 313–316, 1966

    PubMed  CAS  Google Scholar 

  • Sausville EA, Peisach J, Horwitz SB. Effect of chelating agents and metal ions on the degradation of DNA by bleomycin. Biochemistry 17: 2740–2745, 1978a

    Article  PubMed  CAS  Google Scholar 

  • Sausville EA, Stein RW, Peisach J, Horwitz SB. Properties and products of the degradation of DNA by bleomycin and iron (II). Biochemistry 17: 2746–2754, 1978b

    Article  PubMed  CAS  Google Scholar 

  • Schaefer SD, Wright CG, Post JD, Frenkel EP. Cis-platinum vestibular toxicity. Cancer 47: 847–859, 1981

    Article  Google Scholar 

  • Scheithauer W, Ludwig H, Maida E. Acute encephalopathy associated with continuous vincristine sulfate combination therapy: case report. Investigational New Drugs 3: 315–318, 1985

    Article  PubMed  CAS  Google Scholar 

  • Schornagel JH, Vas Engeles MEAG, De Vos D. Bioavailability of methotrexate tablets. pharmaceutisch Weekblad — Scientific Edition 4: 89–90, 1982

    Article  PubMed  CAS  Google Scholar 

  • Sessa C, D’Incales M, Farina P, Rossie C, Cavalli F, et al. Pharmacokinetics of VM-26 after 60 minutes or 24 hours continuous infusion. Proceedings of the American Association of Cancer Research 128: 502, 1982

    Google Scholar 

  • Sessa C, Rossi C, Zuchetti M, Urso R, Cavalli F, et al. Pharmacokinetics of VP16 in patients with impaired renal function. 76th Proceedings of the American Association of Cancer Research 26: 153 (604), 1985

    Google Scholar 

  • Sethi VS, Jackson DV, White DR, Richards ZF, Stuart JJ, et al. Pharmacokinetics of vincristine sulfate in adult cancer patients. Cancer Research 41: 3551–3555, 1981

    PubMed  CAS  Google Scholar 

  • Sethi VS, Kimball JC. Pharmacokinetics of vincristine sulfate in children. Cancer Chemotherapy and Pharmacology 6: 111–115, 1981

    Article  PubMed  CAS  Google Scholar 

  • Shelley MD, Fish RG, Adams M. Biliary excretion of platinum in a patient treated with cis-dichlorodiammineplatinum (II). Antimicrobial Agents and Chemotherapy 27: 275–276, 1985

    Article  PubMed  CAS  Google Scholar 

  • Shen DD, Azarnoff DL. Clinical pharmacokinetics of methotrexate. Clinical Pharmacokinetics 3: 1–13, 1978

    Article  PubMed  CAS  Google Scholar 

  • Siegfried JA, Kennedy KA, Sartorelli AC, Tritton TR. The role of membranes in the mechanism of action of adriamycin. Journal of Biological Chemistry 258: 339–343, 1983

    PubMed  CAS  Google Scholar 

  • Sikic BI, Collins JM, Mimnaugh EG, Gram TE. Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treatment Reports 62: 2011–2017, 1978

    PubMed  CAS  Google Scholar 

  • Sinkule JA. Etoposide: a semisynthetic epipodophyllotoxin. Chemistry, pharmacology, pharmacokinetics, adverse effects and use as an antineoplastic agent. Pharmacotherapy 4: 61–73, 1984

    PubMed  CAS  Google Scholar 

  • Sinkule JA, Hutson P, Hayes FA, Etcubanas E, Evans W. Pharmacokinetics of etoposide (VP-16) in children and adolescents with refractory solid tumors. Cancer Research 44: 3109–3113, 1984a

    PubMed  CAS  Google Scholar 

  • Sinkule JA, Stewart CF, Crom WR, Melton ET, Dahl GV, et al. Teniposide (VM-26) disposition in children with leukemia. Cancer Research 44: 1235–1237, 1984b

    PubMed  CAS  Google Scholar 

  • Sinkule JA, Vogelzang NJ. Clinical pharmacokinetics of continuous doxorubicin infusion (CDI) using an implanted drug administration device (DAD). Proceedings of the American Association of Cancer Research 26: 217, 1985

    Google Scholar 

  • Sirotnak FM, Moccio DM, Dorick DM. Optimization of high-dose methotrexate and leucovorin rescue therapy in L1210 leukemia and sarcoma 180 murine tumor models. Cancer Research 38: 345–353, 1978

    PubMed  CAS  Google Scholar 

  • Sladek NE, Priest J, Doeden D, Mirocha CJ, Pathre S, et al. Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treatment Reports 64: 1061–1066, 1980

    PubMed  CAS  Google Scholar 

  • Smith DK, Omura GA, Ostroy F. Clinical pharmacology of intermediate-dose oral methotrexate. Cancer Chemotherapy and Pharmacology 4: 117–120, 1980

    Article  PubMed  CAS  Google Scholar 

  • Smith PHS, Taylor DM. Distribution and retention of the antitumor agent 195mPt-cis-dichlorodiammineplatinum (II) in man. Journal of Nuclear Medicine 15: 349–351, 1974

    PubMed  CAS  Google Scholar 

  • Smyth RD, Pfeffer M, Scalzo A, Comis RL. Bioavailability and pharmacokinetics of etoposide (VP-16). Seminars in Oncology 12 (Suppl. 2): 48–51, 1985

    PubMed  CAS  Google Scholar 

  • Spector JJ, Zimbler H. Cyclophosphamide pneumonitis. New England Journal of Medicine 307: 251, 1982

    Article  PubMed  CAS  Google Scholar 

  • Spigelman MK, Zappulla RA, Johnson J, Goldsmith SJ, Malis LI, et al. Etoposide-induced blood-brain barrier disruption: effect of drug compared with that of solvents. Journal of Neurosurgery 61: 674–678, 1984

    Article  PubMed  CAS  Google Scholar 

  • Stewart AL, Margisos JM, Wilkinson PM, et al. The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy. Cancer Chemotherapy and Pharmacology 14: 165–167, 1985

    Article  PubMed  CAS  Google Scholar 

  • Stewart DJ, Benjamin RS, Luna M. Human tissue distribution of platinum after cis-diamminedichloroplatinum. Cancer Chemotherapy and Pharmacology 10: 51–54, 1982a

    Article  PubMed  CAS  Google Scholar 

  • Stewart DJ, Leavens M, Maor M, et al. Human central nervous system distribution of cis-diamminedichloroplatinum and use as a radiosensitizer in malignant brain tumors. Cancer Research 42: 2474–2479, 1982b

    PubMed  CAS  Google Scholar 

  • Stewart DJ, Mikhael NZ, Nanji AA, Nair RC, Karew S, et al. Renal and hepatic concentrations of platinum: relationship to cisplatin time, dose, and nephrotoxicity. Journal of Clinical Oncology 3: 1251–1256, 1985a

    PubMed  CAS  Google Scholar 

  • Stewart DJ, Nundy D, Maroun JA, Tetreault L, Prior L. Bioavailability, pharmacokinetics, and clinical effects of an oral preparation of etoposide. Cancer Treatment Reports 69: 269–273, 1985b

    PubMed  CAS  Google Scholar 

  • Stewart DJ, Richard MT, Hugenholtz H, Dennery JM, Belanger R, et al. Penetration of VP-16 (etoposide) into human intracerebral and extracerebral tumors. Journal of Neuro-oncology 2(2): 133–139, 1984a

    Article  PubMed  CAS  Google Scholar 

  • Stewart DJ, Richard MT, Hugenholtz H, Dennery J, Nundy D, et al. Penetration of teniposide (VM-26) into human intracerebral tumors: preliminary observations on the effect of tumor type, rate of drug infusion and prior treatment with amphotericin B or oral glycerol. Journal of Neuro-oncology 2(4): 315–324, 1984b

    Article  PubMed  CAS  Google Scholar 

  • Stoller RC, Hande KR, Jacobs SA, et al. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New England Journal of Medicine 297: 630–634, 1977

    Article  PubMed  CAS  Google Scholar 

  • Stoller RG, Jacobs SA, Drake JC, et al. Pharmacokinetics of high-dose methotrexate (NSC-740). Cancer Chemotherapy Reports 6: 19–24, 1975

    Google Scholar 

  • Struck RF, Kirk MC, Mellett LB, El Dareer S, Hill DC. Urinary metabolites of the antitumor agent cyclophosphamide. Molecular Pharmacology 7: 519–529, 1971

    PubMed  CAS  Google Scholar 

  • Sugita ET, Niebergall PJ. Prednisone. Journal of the American Pharmaceutical Association 15: 529–532, 1975

    Google Scholar 

  • Sutow WW, Sullivan MP. Cyclophosphamide therapy in children with E wing’s sarcoma. Cancer Chemotherapy Reports 23: 55–60, 1962

    CAS  Google Scholar 

  • Szefler SJ, Ellis EF, Brenner M, Rose JQ, Spector SL, et al. Steroid-specific and anticonvulsant interaction aspects of troleandomycin-steroid therapy. Journal of Allergy and Clinical Immunology 69: 455–460, 1982

    Article  PubMed  CAS  Google Scholar 

  • Takanishi S, Bachur NR. Adriamycin metabolism in man: evidence from urinary metabolites. Drug Metabolism and Disposition 4(1): 79–87, 1976

    Google Scholar 

  • Tan C, D’Angio GJ, Exelby PR, et al. The changing management of childhood Hodgkin’s disease. Cancer 35: 808–816, 1975a

    Article  PubMed  CAS  Google Scholar 

  • Tan C, Rosen C, Ghavimi F, Haghbin M, Helson L, et al. Adriamycin (NSC-123127) in pediatric malignancies. Cancer Chemotherapy Reports 6(2): 259–266, 1975b

    Google Scholar 

  • Tattersall MHV, Parker LM, Pitman SW, et al. Clinical pharmacology of high-dose methotrexate (NSC-740). Cancer Chemotherapy Reports Part 3, 6: 25–29, 1975

    Google Scholar 

  • Taylor JR, Halprin KM. Effect of sodium salicylate and indomethacin on methotrexate-serum albumin binding. Archives of Dermatology 113: 588–591, 1977

    Article  PubMed  CAS  Google Scholar 

  • Thompson EB, Harmon JM, Zawydiwski R. Corticosteroid effects on an acute lymphoblastic leukemia cell line: a model for understanding steroid therapy in leukemia research: advances in cell biology and treatment. In Murphy & Gilbert (Eds) Leukemia research: advances in cell biology and treatment, pp. 157–169, Elsevier, New York, 1983

    Google Scholar 

  • Thurman WG, Fernbach DJ, Sullivan MP. Cyclophosphamide therapy in neuroblastoma. New England Journal of Medicine 270: 1336–1340, 1964

    Article  PubMed  CAS  Google Scholar 

  • Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet 1: 256–258, 1986

    Article  PubMed  CAS  Google Scholar 

  • Tritton TR, Yee G. The anticancer agent adriamycin can be actively cytotoxic without entering cells. Science 217: 248–250, 1982

    Article  CAS  Google Scholar 

  • Umezawa H. Recent studies on biochemistry and action of bleomycin. In Carter & Cooke (Eds) Bleomycin: current status and new developments, pp. 15–19, Academic Press, New York, 1978

    Google Scholar 

  • Uribe M, Schalm SW, Summerskill WHJ, Go VLW. Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. Gut 19: 1131–1135, 1978

    Article  PubMed  CAS  Google Scholar 

  • Valerino DM, John DG, Zaharko DS, et al. Studies of the metabolism of methotrexate by intestinal flora. I. Identification and study of biological properties of the metabolite 4-amino-4-deoxy-N10-methylpteroic acid. Biochemical Pharmacology 21: 821–831, 1972

    Article  PubMed  CAS  Google Scholar 

  • Van den Berg HW, Desai ZR, Wilson R, Kennedy G, Bridger JM, et al. The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemotherapy and Pharmacology 8: 215–219, 1982

    Article  PubMed  Google Scholar 

  • Van Maanen JMS, De Ruiter C, DeVries J, Kootstra PR, Gobas F, et al. The role of metabolic activation by cytochrome P-450 in covalent binding of VP-16-213 to rat liver and hela cell microsomal proteins. European Journal of Clinical Oncology 21: 1099–1106, 1985a

    Article  Google Scholar 

  • Van Maanen JMS, De Ruiter C, Kootstra PR, Laaleur MVM, DeVries J, et al. Inactivation of OX174 DNA by the orthoquinone derivative or its reduction product of the antitumor agent VP-16-213. European Journal of Clinical Oncology 21: 1215–1218, 1985b

    Article  Google Scholar 

  • Vermorken JB, van der Vijgh WJF, Klein I, Gall HE, Pinedo HM. Pharmacokinetics of free platinum species following rapid, 3-hr and 24-hr infusions of cis-diamminedichloroplatinum (II) and its therapeutic implications. European Journal of Cancer and Clinical Oncology 18: 1069–1074, 1982

    Article  CAS  Google Scholar 

  • Vermorken JB, van der Vijgh WJF, Klein I, Gall HE, van Groeningen CJ, et al. Pharmacokinetics of free and total platinum species after rapid and prolonged infusions of cisplatin. Clinical Pharmacology and Therapeutics 39: 136–144, 1986

    Article  PubMed  CAS  Google Scholar 

  • Vermorken JB, van der Vijgh WJF, Pinedo HM. Pharmacokinetic evidence for an enterohepatic circulation in a patient treated with cis-dichlorodiammineplatinum (II). Research Communications in Chemical Pathology and Pharmacology 28: 319–328, 1980

    PubMed  CAS  Google Scholar 

  • Voelcker G, Wagner T, Hohorst HJ. Identification and pharmacokinetics of cyclophosphamide (NSC-26271) metabolites in vivo. Cancer Treatment Reports 60: 415–422, 1976

    PubMed  CAS  Google Scholar 

  • Vogelzang NJ, Raghavan D, Kennedy BJ. VP-16-213 (Etoposide): the mandrake root from Issyk-Kul. American Journal of Medicine 72: 136–144, 1982

    Article  PubMed  CAS  Google Scholar 

  • Von Hoff DD, Layard MW, Basa P, Davis HL, Von Hoff AL, et al. Risk factors for doxorubicin-induced congestive heart failure. Annals of Internal Medicine 91: 710–717, 1979a

    Google Scholar 

  • Von Hoff DD, Rozencweig M, Layard M, Slavik M, Muggia F. Daunomycin-induced cardiotoxicity in children and adults. American Journal of Medicine 62: 200–208, 1977

    Article  Google Scholar 

  • Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B. Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Research 34: 3487–3491, 1974

    PubMed  CAS  Google Scholar 

  • Wang JJ, Holland JF, Sinks LF. Phase II study of adriamycin (NSC-123127) in childhood solid tumors. Cancer Chemotherapy Reports 6(2): 267–270, 1975

    Google Scholar 

  • Wang LH, Lee CS, Majeske BC, Marbury TC. Clearance and recovery calculations in hemodialysis: application to plasma, red blood cells and dialysate measurements for cyclophosphamide. Clinical Pharmacology and Therapeutics 29: 365–372, 1981

    Article  PubMed  CAS  Google Scholar 

  • Wang Y, Sutow WW, Romsdahl MM, Perey C. Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma. Cancer Treatment Reports 63: 405–410, 1979

    PubMed  CAS  Google Scholar 

  • Wassner SJ, Pennisi AJ, Malakzadeh MH, Fine RN. The adverse effect of anticonvulsant therapy on renal allograft survival. Journal of Pediatrics 88: 134–137, 1976

    Article  PubMed  CAS  Google Scholar 

  • Weiss AJ, Metter GE, Fletcher WS, Wilson WL, Grage TB, et al. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treatment Reports 60: 813–822, 1976

    PubMed  CAS  Google Scholar 

  • Weiss RB, Poster DS. The renal toxicity of cancer chemotherapeutic agents. Cancer Treatment Review 9: 37–56, 1982

    Article  CAS  Google Scholar 

  • Wheeler C, Rader R, Kessel D. Membrane alterations associated with progressive adriamycin resistance. Biochemical Pharmacology 31(16): 2691–2693, 1982

    Article  PubMed  CAS  Google Scholar 

  • Wilbur JR, Sutow WW, Sullivan MP, Gottlieb JA. Chemotherapy of sarcomas. Cancer 36: 765–769, 1975

    Article  PubMed  CAS  Google Scholar 

  • Williams WM, Chen TS, Huang KC. Effect of penicillin on the renal tubular secretion of methotrexate in the monkey. Cancer Research 44: 1913–1917, 1984

    PubMed  CAS  Google Scholar 

  • Witten J, Fredriksen PL, Mouridsen HT. The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol. Acta Pharmacologica et Toxicologica 46: 392–394, 1980

    Article  PubMed  CAS  Google Scholar 

  • Wollner N, Burchenal JH, Lieberman PH, et al. Non-Hodgkin’s lymphoma in children. Medical and Pediatric Oncology 1: 235–263, 1975

    Article  PubMed  CAS  Google Scholar 

  • Woods WG, O’Leary M, Nesbit ME. Life-threatening neuropathy and hepatic toxicity in infants during induction therapy for acute lymphoblastic leukemia. Journal of Pediatrics 98: 642–645, 1981

    Article  PubMed  CAS  Google Scholar 

  • Wozniak AJ, Glisson BS, Hande KR, Ross WE. Inhibition of etoposide-induced DNA damage and cytotoxicity in L1210 cells by dehydrogenase inhibitors and other agents. Cancer Research 44: 626–632, 1984

    PubMed  CAS  Google Scholar 

  • Wozniak AJ, Ross WE. DNA damage as a basis for 4′-demethylepipodophyllotoxin-9-(4,6-0-ethylidene-β-D-glucopyranoside) (etoposide) cytotoxicity. Cancer Research 43: 120–124, 1983

    PubMed  CAS  Google Scholar 

  • Yagoda A, Murkherji B, Young C, Etcubanas E, Lamonte C, et al. Bleomycin, an antitumor antibiotic: clinical experience in 274 patients. Annals of Internal Medicine 77: 861–870, 1972

    PubMed  CAS  Google Scholar 

  • Yalowich JC, Goldman ID. Analysis of the inhibitory effects of VP-16-213 (etoposide) and podophyllotoxin on thymidine transport and metabolism in Ehrlich Ascites tumor cells in vitro. Cancer Research 44: 984–989, 1984

    PubMed  CAS  Google Scholar 

  • Yalowich JC, Ross WE. Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Cancer Research 45: 1651–1656, 1985

    PubMed  CAS  Google Scholar 

  • Yalowich JC, Fry DW, Goldman D. Teniposide (VM-26) and etoposide (VP-16-213)-induced augmentation of methotrexate transport and polyglutamylation in Ehrlich ascites tumor cells in vitro. Cancer Research 42: 3648–3653, 1982

    PubMed  CAS  Google Scholar 

  • Yee GC. Cisplatin. In Taylor & Diers Caviness (Eds) A textbook for the clinical application of therapeutic drug monitoring, pp. 413–420, Abbott Laboratories, Diagnostics Division, Irving, 1986

    Google Scholar 

  • Yee GC, Crom WR, Lee FH, Smyth RD, Evans WE. Bleomycin disposition in children with cancer. Clinical Pharmacology and Therapeutics 33: 668–673, 1983

    Article  PubMed  CAS  Google Scholar 

  • Young CW, Raymond V. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives. Cancer Treatment Reports 70: 51–63, 1986

    PubMed  CAS  Google Scholar 

  • Young JA, Howell SB, Green WR. Pharmacokinetics and toxicity of 5-day continuous infusion of vinblastine. Cancer Chemotherapy Pharmacology 12: 43–45, 1984

    Article  CAS  Google Scholar 

  • Zaharko DS, Dedrick RL, Bischoff KB, et al. Methotrexate tissue distribution: prediction by a mathematical model. Journal of the National Cancer Institute 46: 775–784, 1971

    PubMed  CAS  Google Scholar 

  • Zaharko DS, Dedrick RL, Peale AL, et al. Relative toxicity of methotrexate in several tissues of mice bearing Lewis lung carcinoma. Journal of Pharmaceutical Experimental Therapeutics 189: 585–592, 1974

    CAS  Google Scholar 

  • Ziegler JL, Morrow RH, Fass L, et al. Treatment of Burkitt’s tumor with cyclophosphamide. Cancer 26: 474–484, 1970

    Article  PubMed  CAS  Google Scholar 

  • Zurek WK, Ojima Y, Anderson LL, et al. Pharmacologic studies of methotrexate in man. Gynecologic and Obstetric Investigations 126: 331–338, 1968

    Google Scholar 

  • Zwelling LA, Kohn KW. Mechanism of action of cis-dichlorodiammine platinum (II). Cancer Treatment Reports 63: 1439–1444, 1979

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmacokinetics and Pharmacodynamics Section, Pharmaceutical Division, St Jude Children’s Research Hospital, 332 North Lauderdale, Memphis, TN, 38101, USA

    William R. Crom, Anne M. Glynn-Barnhart, John H. Rodman, Mary E. Teresi, Ronald E. Kavanagh, Michael L. Christensen, Mary V. Relling &  William E. Evans

  2. Center for Pediatric Pharmacokinetics and Therapeutics, Department of Clinical Pharmacy, University of Tennessee, Memphis, USA

    William R. Crom, Anne M. Glynn-Barnhart, John H. Rodman, Mary E. Teresi, Ronald E. Kavanagh, Michael L. Christensen, Mary V. Relling &  William E. Evans

Authors
  1. William R. Crom
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne M. Glynn-Barnhart
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. John H. Rodman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mary E. Teresi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ronald E. Kavanagh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Michael L. Christensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Mary V. Relling
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. William E. Evans
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Crom, W.R., Glynn-Barnhart, A.M., Rodman, J.H. et al. Pharmacokinetics of Anticancer Drugs in Children. Clin-Pharmacokinet 12, 168–213 (1987). https://doi.org/10.2165/00003088-198712030-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-198712030-00002

Keywords

Search

Navigation